Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1
Name
Lin-2011-Loss of the retinobl.pdf
Size
1.87 MB
Format
Adobe PDF
Checksum (MD5)
f3c0bfde94e29573e07b661d40e25e91
Author(s) • • • • • • • • •
Lin, Wenchu
Cao, Jian
Liu, Jiayun
Beshiri, Michael L.
Fujiwara, Yuko
Francis, Joshua M.
Cherniack, Andrew D.
Geisen, Christoph
Blair, Lauren P.
Zou, Mike R.
Date Issued
August 2011
Journal
Proceedings of the National Academy of Sciences of the United States of America
Publisher
National Academy of Sciences (U.S.)
Citation
Lin, W. et al. “Loss of the Retinoblastoma Binding Protein 2 (RBP2) Histone Demethylase Suppresses Tumorigenesis in Mice Lacking Rb1 or Men1.” Proceedings of the National Academy of Sciences 108.33 (2011): 13379–13386. Web.
Version
Final published version
Abstract
Aberrations in epigenetic processes, such as histone methylation, can cause cancer. Retinoblastoma binding protein 2 (RBP2; also called JARID1A or KDM5A) can demethylate tri- and dimethylated lysine 4 in histone H3, which are epigenetic marks for transcriptionally active chromatin, whereas the multiple endocrine neoplasia type 1 (MEN1) tumor suppressor promotes H3K4 methylation. Previous studies suggested that inhibition of RBP2 contributed to tumor suppression by the retinoblastoma protein (pRB). Here, we show that genetic ablation of Rbp2 decreases tumor formation and prolongs survival in Rb1+/− mice and Men1-defective mice. These studies link RBP2 histone demethylase activity to tumorigenesis and nominate RBP2 as a potential target for cancer therapy.
MIT Department
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1073/pnas.1110104108